Belgian-Dutch immunology company argenx (ARGX.BR), will buy Forte Biosciences (FBRX.O), to add experimental autoimmune drug FB102 to its portfolio, the company said on Monday.
Argenx will pay $77 a share in cash, valuing the U.S. drug developer at about $2.2 billion, in a deal that gives it a first-in-class anti-CD122 antibody that has shown early promise in vitiligo and celiac disease.
By Reuters
Source: reuters.com
Taubert joined J&J’s executive committee in 2018 when she was elevated from leading the pharmaceuticals unit’s operations in the Americas to heading up the entire department, just as her predecessor Joaquin Duato moved up to become then-CEO Alex Gorsky’s right hand. She was named one of the Fiercest Women in Life Sciences in 2019.
BioNTech has named the head of Swedish pharmaceutical company Sobi to be its next CEO, marking the latest step of a transformation that will see the prominent messenger RNA drugmaker become more of an oncology specialist.
I am one of thousands of clients who has had something flagged as a potential issue, then later found no further treatment was required. Some doctors say this causes unnecessary anxiety and that patients should only rely on national screening programmes.
